Who is sponsoring NCT04797377?

NCT04797377 is sponsored by Nadezhda Women's Health Hospital.

What drugs are being tested in NCT04797377?

Interventions in NCT04797377: Autologous ovarian PRP injection.

What condition does NCT04797377 study?

NCT04797377 studies Poor Ovarian Reserve.

Is NCT04797377 still recruiting?

NCT04797377 is currently completed. Last updated 6 April 2022.

Last reviewed 2022-04-06 · How we verify

NCT04797377

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response

Completed NA Last updated 6 April 2022

What this trial tests

NA trial testing Autologous ovarian PRP injection in Poor Ovarian Reserve in 66 participants. Completed in 4 September 2021.

Timeline

16 March 2021

Primary endpoint
4 September 2021

4 September 2021

Quick facts

Lead sponsor	Nadezhda Women's Health Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	16 March 2021
Primary completion	4 September 2021
Estimated completion	4 September 2021
Sites	1 location across Bulgaria

Drugs / interventions tested

Autologous ovarian PRP injection — full drug profile →

Conditions studied

Poor Ovarian Reserve — all drugs for Poor Ovarian Reserve →

Sponsor

Nadezhda Women's Health Hospital

Who can join

Adults 30 to 46, female only, with Poor Ovarian Reserve. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Reproductive age women diagnosed with poor ovarian response (POR) based on Bologna criteria with a history of at least two prior failed ICSI cycle will be recruited for the study. Antral follicle count (AFC), serum anti-mullerian hormone (AMH), and early follicular phase serum follicle stimulating hormone (FSH) levels will determined at baseline. Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols and will be injected to both ovaries. Ovarian reserve parameters and ICSI outcomes will be determined.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic roles of platelet-rich plasma to restore female reproductive and endocrine dysfunction.
Wang X, Li J, Lu W, Gao F, et al · · 2024 · cited 8× · PMID 38654928 · DOI 10.3389/fendo.2024.1374382
Ovarian Aging: Mechanisms, Age-Related Disorders, and Therapeutic Interventions.
Liu X, Zhao Y, Feng Y, Wang S, et al · · 2025 · cited 3× · PMID 41256733 · DOI 10.1002/mco2.70481
Research trends on platelet-rich plasma in improving ovarian dysfunction: A bibliometric and visualization analysis.
Liu F, Li J, Li J, Lan M, et al · · 2025 · PMID 41079455 · DOI 10.1016/j.reth.2025.09.010

Verify or expand the search:

Other recruiting trials for Poor Ovarian Reserve

Currently open trials in the same condition.

NCT07020546 — Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score · NA · recruiting

Other Nadezhda Women's Health Hospital trials

Trials by the same sponsor.

NCT05421364 — Effects of Intrauterine Administration of Autologous PBMC on the Endometrial Cells Populations · NA · recruiting
NCT05775211 — Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations · NA · recruiting
NCT05775198 — Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome · NA · recruiting
NCT05257213 — Heparin Solution Versus Anti-adhesion Barrier Gel for Intrauterine Adhesions Prevention After Operative Hysteroscopy · NA · recruiting
NCT05161247 — Reproductive Outcome After Sperm Selection for Intracytoplasmic Sperm Injection (ICSI) Using Zona Pellucida Proteins · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04797377 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nadezhda Women's Health Hospital
Last refreshed: 6 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04797377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing